Merck & Co. has agreed to pay $688 million to settle two shareholder class actions in federal court in Newark claiming it made false and misleading statements about the efficacy of cholesterol-reducing drug Vytorin.
The settlement, announced Thursday, includes $215 million for class members in a suit against Merck and $473 million for the class in a suit against Schering-Plough Corp., which merged with Merck in 2009 and sold Vytorin in a joint venture.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
